Sana's Terry Fry to Spearhead New Regenerative, Cell & Gene Therapy Endeavor

Dr. Terry Fry, M.D., a leader in chimeric antigen receptor T-cell (CAR-T) therapies and senior vice president, head of T-cell therapeutics at Sana Biotechnology, will be heading a newly created Gates Institute. The state-of-the-art facility will be on the University of Colorado Anschutz Medical Campus, where Fry is also a clinical professor of pediatric oncology.